UBS Group AG - ESPERION THERAPEUTICS INC NE ownership

ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 141 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2022. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.

Quarter-by-quarter ownership
UBS Group AG ownership history of ESPERION THERAPEUTICS INC NE
ValueSharesWeighting
Q3 2023$30,537
-60.2%
31,160
-43.6%
0.00%
Q2 2023$76,730
-24.1%
55,202
-13.2%
0.00%
Q1 2023$101,110
-30.8%
63,591
+171.0%
0.00%
Q4 2022$146,162
+53.9%
23,461
+66.6%
0.00%
Q3 2022$95,000
-8.7%
14,084
-14.4%
0.00%
Q2 2022$104,000
+62.5%
16,454
+18.9%
0.00%
Q1 2022$64,000
-80.2%
13,844
-78.6%
0.00%
Q4 2021$323,000
-22.4%
64,742
+87.6%
0.00%
Q3 2021$416,000
-63.0%
34,516
-35.0%
0.00%
Q2 2021$1,124,000
-39.8%
53,140
-20.2%
0.00%
-100.0%
Q1 2021$1,867,000
+403.2%
66,575
+366.2%
0.00%
Q4 2020$371,000
-57.6%
14,279
-39.4%
0.00%
Q3 2020$875,000
-69.7%
23,558
-58.1%
0.00%
-100.0%
Q2 2020$2,886,000
-32.9%
56,248
-58.8%
0.00%
-50.0%
Q1 2020$4,302,000
+11.0%
136,423
+110.0%
0.00%
+100.0%
Q4 2019$3,874,000
+835.7%
64,965
+475.2%
0.00%
Q3 2019$414,000
-64.0%
11,295
-54.4%
0.00%
Q2 2019$1,151,000
+15.4%
24,747
-0.3%
0.00%
Q1 2019$997,000
-88.3%
24,821
-86.6%
0.00%
-100.0%
Q4 2018$8,531,000
+171.2%
185,442
+161.5%
0.00%
+300.0%
Q3 2018$3,146,000
+100.9%
70,904
+77.4%
0.00%0.0%
Q2 2018$1,566,000
-80.5%
39,963
-64.0%
0.00%
-66.7%
Q1 2018$8,020,000
+45.2%
110,882
+32.1%
0.00%
+50.0%
Q4 2017$5,524,000
+5.8%
83,907
-19.5%
0.00%0.0%
Q3 2017$5,223,000
-25.8%
104,191
-31.5%
0.00%
-50.0%
Q2 2017$7,038,000
+97.1%
152,061
+50.4%
0.00%
+100.0%
Q1 2017$3,571,000
+489.3%
101,131
+108.9%
0.00%
Q4 2016$606,000
-11.4%
48,419
-1.9%
0.00%
Q3 2016$684,000
+388.6%
49,373
+250.6%
0.00%
Q2 2016$140,000
-26.3%
14,081
+25.2%
0.00%
Q1 2016$190,000
-94.0%
11,247
-92.1%
0.00%
-100.0%
Q4 2015$3,183,000
+114.8%
143,012
+127.7%
0.00%
+100.0%
Q3 2015$1,482,000
+39.0%
62,797
+381.4%
0.00%0.0%
Q2 2015$1,066,000
+1737.9%
13,045
+1993.9%
0.00%
Q1 2015$58,000
-69.3%
623
-86.6%
0.00%
Q4 2014$189,0004,6570.00%
Other shareholders
ESPERION THERAPEUTICS INC NE shareholders Q2 2022
NameSharesValueWeighting ↓
Meditor Group Ltd 2,679,835$69,675,00019.39%
Endurant Capital Management LP 207,293$5,390,0001.94%
Bellevue Group AG 5,138,451$133,599,0001.53%
Rhenman & Partners Asset Management AB 592,225$15,398,0001.26%
PLATINUM INVESTMENT MANAGEMENT LTD 1,562,869$40,635,0000.93%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 31,434$817,0000.62%
WASATCH ADVISORS LP 3,998,010$103,949,0000.51%
HAMILTON LANE ADVISORS LLC 46,181$1,201,0000.45%
Boxer Capital, LLC 500,000$13,000,0000.42%
DCF Advisers, LLC 38,500$1,001,0000.41%
View complete list of ESPERION THERAPEUTICS INC NE shareholders